PRLD - Prelude Therapeutics Incorporated

-

$undefined

N/A

(N/A)

Prelude Therapeutics Incorporated NasdaqGS:PRLD Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Location: 175 Innovation Boulevard, Wilmington, DE, 19805, United States | Website: https://preludetx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-30.23M

Cash

99.07M

Avg Qtr Burn

-26.33M

Short % of Float

4.84%

Insider Ownership

11.37%

Institutional Own.

69.69%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Initiation

PRT543 (PRMT5 inhibitor) Details
Myelofibrosis, Solid tumor/s, Myelodysplastic syndrome, Cancer

Phase 1

Data readout

PRT3645 (CDK4/6 inhibitor) Details
Head and neck cancer, Glioblastoma, Non-small cell lung carcinoma, Breast cancer

Phase 1

Data readout

PRT3789 [SMARCA2 degrader] Details
Non-small cell lung carcinoma, gastric and esophageal cancer

Phase 1

Data readout

Phase 1

Data readout

PRT2527 (CDK9 inhibitor) Details
Acute myeloid leukemia, Hematologic malignancies

Phase 1

Update

PRT1419 (MCL1 inhibitor) Details
Hematologic malignancies, B-cell malignancies, Relapsed/refractory acute myeloid leukemia, Solid tumor/s

Failed

Discontinued

PRT811 (PRMT5 inhibitor) Details
primary central nervous system lymphomas, Cancer, Glioblastoma

Failed

Discontinued